Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9692.7222
Address
Level 4 96-100 Albert Road South Melbourne, Victoria (VIC) 3205
Description
Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. It operates under the Corporate and Research, and Pharmaceutical-Epichem segments. The Corporate and Research segment includes corporate overhead expenses. The Pharmaceutical-Epichem segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.1 - 0.26
Trade Value (12mth)
AU$36,078.00
1 week
0%
1 month
9.09%
YTD
-27.27%
1 year
-52%
All time high
4.74
EPS 3 yr Growth
481.00%
EBITDA Margin
N/A
Operating Cashflow
-$5m
Free Cash Flow Return
-68.90%
ROIC
-118.60%
Interest Coverage
N/A
Quick Ratio
12.40
Shares on Issue (Fully Dilluted)
483m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
24 April 25 |
Notice of Quarterly Shareholder Update Webinar
×
Notice of Quarterly Shareholder Update Webinar |
22 April 25 |
Appointment of Chief Financial Officer
×
Appointment of Chief Financial Officer |
17 April 25 |
Leadership team strengthened with strategic appointments
×
Leadership team strengthened with strategic appointments |
04 April 25 |
NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells
×
NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells |
01 April 25 |
NUZ-001 Shows Positive Results in Human 3D Brain Model
×
NUZ-001 Shows Positive Results in Human 3D Brain Model |
24 March 25 |
NUZ-001 shows promising respiratory outcome
×
NUZ-001 shows promising respiratory outcome |
17 March 25 |
Neurizon Commences Initiatives to Lift Clinical Hold
×
Neurizon Commences Initiatives to Lift Clinical Hold |
17 February 25 |
Appendix 4D - Half-year Financial Report - 31 December 2024
×
Appendix 4D - Half-year Financial Report - 31 December 2024 |
17 February 25 |
Neurizon to Present Latest Results and Key Updates
×
Neurizon to Present Latest Results and Key Updates |
17 February 25 |
FDA Guidance on NUZ-001 IND Application
×
FDA Guidance on NUZ-001 IND Application |
11 February 25 |
Notice of Company Update Webinar
×
Notice of Company Update Webinar |
07 February 25 |
Change of Director's Interest Notices x3
×
Change of Director's Interest Notices x3 |
05 February 25 |
US Patent granted for NUZ-001
×
US Patent granted for NUZ-001 |
31 January 25 |
Notification regarding unquoted securities - NUZ
×
Notification regarding unquoted securities - NUZ |
29 January 25 |
Appendix 4C & Quarterly Update
×
Appendix 4C & Quarterly Update |
17 January 25 |
Neurizon updates on NUZ-001 IND Application
×
Neurizon updates on NUZ-001 IND Application |
16 January 25 |
Change of Share Registry
×
Change of Share Registry |
27 December 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
27 December 24 |
Application for quotation of securities - NUZ
×
Application for quotation of securities - NUZ |
18 December 24 |
Neurizon Files IND Application to Support HEALEY ALS Trial
×
Neurizon Files IND Application to Support HEALEY ALS Trial |
17 December 24 |
Neurizon Granted OMPD for NUZ-001 in Europe
×
Neurizon Granted OMPD for NUZ-001 in Europe |
16 December 24 |
Positive 8-month Interim Data from OLE Study
×
Positive 8-month Interim Data from OLE Study |
12 December 24 |
Neurizon Presents Company Update and 2025 Outlook
×
Neurizon Presents Company Update and 2025 Outlook |
11 December 24 |
Neurizon Receives Additional R&D Tax Incentive Rebate
×
Neurizon Receives Additional R&D Tax Incentive Rebate |
05 December 24 |
Notice of Company Update Webinar
×
Notice of Company Update Webinar |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.